RU2727805C2 - Аминопиразиновые соединения со свойствами антагониста a2a - Google Patents

Аминопиразиновые соединения со свойствами антагониста a2a Download PDF

Info

Publication number
RU2727805C2
RU2727805C2 RU2017120853A RU2017120853A RU2727805C2 RU 2727805 C2 RU2727805 C2 RU 2727805C2 RU 2017120853 A RU2017120853 A RU 2017120853A RU 2017120853 A RU2017120853 A RU 2017120853A RU 2727805 C2 RU2727805 C2 RU 2727805C2
Authority
RU
Russia
Prior art keywords
methyl
amino
carboxamide
pyrazine
oxazol
Prior art date
Application number
RU2017120853A
Other languages
English (en)
Russian (ru)
Other versions
RU2017120853A (ru
RU2017120853A3 (enExample
Inventor
Жунцзе КУАН
Полин ТИНГ
Амджад Али
Хэпин У
Майкл БЕРЛИН
Эндрю СТЭМФОРД
Хунву ВАН
Ган ЧЖОУ
Дэвид Ким
Цяолинь ДЭН
Йеон-Хее ЛИМ
Юнун ЮЙ
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2017120853A publication Critical patent/RU2017120853A/ru
Publication of RU2017120853A3 publication Critical patent/RU2017120853A3/ru
Application granted granted Critical
Publication of RU2727805C2 publication Critical patent/RU2727805C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017120853A 2014-11-18 2015-11-13 Аминопиразиновые соединения со свойствами антагониста a2a RU2727805C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081262P 2014-11-18 2014-11-18
US62/081,262 2014-11-18
PCT/US2015/060509 WO2016081290A1 (en) 2014-11-18 2015-11-13 Aminopyrazine compounds with a2a antagonist properties

Publications (3)

Publication Number Publication Date
RU2017120853A RU2017120853A (ru) 2018-12-19
RU2017120853A3 RU2017120853A3 (enExample) 2019-06-17
RU2727805C2 true RU2727805C2 (ru) 2020-07-24

Family

ID=56014406

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017120853A RU2727805C2 (ru) 2014-11-18 2015-11-13 Аминопиразиновые соединения со свойствами антагониста a2a

Country Status (11)

Country Link
US (1) US10472347B2 (enExample)
EP (1) EP3220910B1 (enExample)
JP (2) JP6779204B2 (enExample)
KR (1) KR20170083136A (enExample)
CN (1) CN107106558A (enExample)
AU (1) AU2015350315B2 (enExample)
BR (1) BR112017010261A2 (enExample)
CA (1) CA2967944C (enExample)
MX (1) MX381180B (enExample)
RU (1) RU2727805C2 (enExample)
WO (1) WO2016081290A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
EP3594216B1 (en) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020532541A (ja) 2017-08-31 2020-11-12 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシンa2b受容体およびアデノシンa2a受容体を調節するための化合物および方法
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての多環式化合物
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
EP3616753A1 (en) * 2018-08-31 2020-03-04 Corvus Pharmaceuticals, Inc. Compounds for modulating adenosine a2b receptor and adenosine a2a receptor
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
TW202128650A (zh) * 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物
CN111285798A (zh) * 2020-04-09 2020-06-16 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺盐酸盐的合成方法
CN111423364A (zh) * 2020-05-19 2020-07-17 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺的合成方法
EP3929189A1 (en) * 2020-06-25 2021-12-29 Bayer Animal Health GmbH Novel heteroaryl-substituted pyrazine derivatives as pesticides
TW202304865A (zh) 2021-03-23 2023-02-01 美商百愛及生物醫藥公司 Nlrp3發炎體之抑制劑
CN119053602A (zh) 2022-01-28 2024-11-29 柏奥艾奇实验室公司 Nlrp3炎性体的n-氧化物抑制剂
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
US12516018B2 (en) * 2023-03-30 2026-01-06 Brandeis University Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12509459B2 (en) 2024-03-26 2025-12-30 BioAge Labs, Inc. Inhibitors of NLRP3 inflammasome

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
US20050113387A1 (en) * 2003-10-27 2005-05-26 Fujisawa Pharmaceutical Co. Ltd. Pyrazine derivatives and pharmaceutical use thereof
US20090233944A1 (en) * 2005-03-04 2009-09-17 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
US20100075989A1 (en) * 2002-12-17 2010-03-25 Astrazeneca Ab Novel Compounds Having Selective Inhibiting Effect at GSK3
US20120065205A1 (en) * 2009-06-01 2012-03-15 Mercer Swati P Pyrazine carboxamide orexin receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075989A1 (en) * 2002-12-17 2010-03-25 Astrazeneca Ab Novel Compounds Having Selective Inhibiting Effect at GSK3
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
US20050113387A1 (en) * 2003-10-27 2005-05-26 Fujisawa Pharmaceutical Co. Ltd. Pyrazine derivatives and pharmaceutical use thereof
US20090233944A1 (en) * 2005-03-04 2009-09-17 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
RU2407739C2 (ru) * 2005-03-04 2010-12-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗИН-2-КАРБОКСАМИДА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR5
US20120065205A1 (en) * 2009-06-01 2012-03-15 Mercer Swati P Pyrazine carboxamide orexin receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELINE BONNEFOUS et al.: "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, vol.15, no.4, pages 1197-1200 *
CELINE BONNEFOUS et al.: "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, vol.15, no.4, pages 1197-1200. *

Also Published As

Publication number Publication date
AU2015350315A1 (en) 2017-05-18
BR112017010261A2 (pt) 2018-02-06
JP2017533946A (ja) 2017-11-16
EP3220910A1 (en) 2017-09-27
US10472347B2 (en) 2019-11-12
CA2967944A1 (en) 2016-05-26
CN107106558A (zh) 2017-08-29
KR20170083136A (ko) 2017-07-17
RU2017120853A (ru) 2018-12-19
WO2016081290A1 (en) 2016-05-26
JP6779204B2 (ja) 2020-11-04
CA2967944C (en) 2020-11-17
EP3220910A4 (en) 2018-04-25
MX2017006483A (es) 2017-09-12
MX381180B (es) 2025-03-12
EP3220910B1 (en) 2020-01-15
AU2015350315B2 (en) 2020-06-25
RU2017120853A3 (enExample) 2019-06-17
US20180327385A1 (en) 2018-11-15
JP2020193211A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
RU2727805C2 (ru) Аминопиразиновые соединения со свойствами антагониста a2a
AU2014338549B2 (en) Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
EP3717488B1 (en) Substituted furanopyrimidine compounds as pde1 inhibitors
US9233977B2 (en) Leucine-rich repeat kinase enzyme activity
US9725453B2 (en) Imidazotriazinone compounds
EP3253390B1 (en) Aminoquinazoline compounds as a2a antagonist
EP3331532B1 (en) Substituted aminoquinazoline compounds as a2a antagonist
AU2016261031A1 (en) Substituted quinoxaline derivatives
KR20200022027A (ko) 아데노신 A2A 수용체의 이미다조[1,2,a]피라진 조절물질
WO2014159591A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
WO2016086200A9 (en) 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
JP2021533179A (ja) ピラジン化合物およびその使用
KR20160056896A (ko) Pim 키나아제 억제제로서 유용한 푸로- 및 티에노-피리딘 카복사미드 화합물
US12448368B2 (en) Indole compounds as androgen receptor modulators
CN115181092B (zh) 吡嗪化合物和其用途
RU2809631C2 (ru) Пиразиновые соединения и их применения
US20240270748A1 (en) Tricyclic heterocycles
TW202545926A (zh) 作為菸鹼醯胺n—甲基轉移酶抑制劑的哌啶衍生物
FR3052451A1 (enExample)
KR20250172652A (ko) 신경학적 및 정신의학적 장애의 치료에 유용한 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 1,6-나프티리딘 유도체
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK1201265B (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity